Metabolic Obesity, Adipocytokines, and Inflammatory Markers in Asian Indians—CURES-124
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
AIM: This study looked at the association of adipokines, inflammatory and oxidative stress markers in subjects with the following phenotypes: metabolically healthy, nonobese (MHNO), metabolically healthy, obese (MHO), metabolically obese, nonobese (MONO), and metabolically obese, obese (MOO). MATERIALS AND METHODS: Subjects with MHNO (n=462), MHO (n=192), MONO (n=315), and MOO (n=335) were randomly selected from the Chennai Urban Rural Epidemiology Study. Adiponectin, visfatin, resistin, high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), oxidized low-density lipoprotein (LDL), and monocyte chemoattractant protein-1 (MCP-1) were measured by enzyme-linked immunosorbent assay. RESULTS: Levels of adiponectin were lowest in the MOO group, followed by the MONO, MHO, and the MHNO groups (P=0.042), whereas the levels of visfatin (P=0.042) and resistin (P=0.043) were highest in the MOO group, followed by the MONO, MHO, and the MHNO groups. Levels of hs-CRP (P=0.029), TNF-α (P=0.036), IL-6 (P=0.042), oxidized LDL (P=0.036), and MCP-1 (P=0.039) increased from the MHNO to MHO to MONO to MOO phenotypes. Linear regression analysis of the parameters with body mass index (BMI) and metabolic syndrome components showed that adiponectin is negatively associated with abdominal obesity (β=-0.060; P=0.039) and BMI (β=-0.076; P=0.009) and that TNF-α is negatively associated with high-density lipoprotein levels (β=0.114, P=0.049) even after adjusting for age and gender. hs-CRP (β=0.112, P=0.020) and oxidized LDL (β=0.114, P=0.050) showed a positive association with systolic blood pressure even after adjusting for age and gender. CONCLUSIONS: The metabolically obese phenotype is characterized by altered adipokine and inflammatory profiles, which could make this phenotype at high risk for type 2 diabetes mellitus and cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“There is convincing evidence that metabolic disorders like Type 2 diabetes (T2DM) and Metabolic syndrome (MS) and are associated with obesity [1].”
Wildman, R. P. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.15.1617 · Cited by 1,618
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases
Hajer, G. R., van Haeften, T. W., & Visseren, F. L. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn387 · Cited by 1,410
Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Li, G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31021 · Cited by 1,310
IL-6 signal transduction and its physiological roles: the signal orchestration model
Kamimura, D., Ishihara, K., & Hirano, T. (2003) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/s10254-003-0012-2 · Cited by 673
The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals
Blüher, M. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283346ccc · Cited by 632
Body Fat Distribution and Insulin Resistance in Healthy Asian Indians and Caucasians
Raji, A., Seely, E. W., Arky, R. A., & Simonson, D. C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.7992 · Cited by 541 · cited 1×
“13 To characterize these metabolic disturbances in the secretory pattern of adipose tissue, we chose to study the circulating levels of adiponectin, resistin, visfatin, hs-CRP, TNF-a , IL-6, MCP-1, and oxidized LDL in the various body size phenotypes.”
Koerner, A., Kratzsch, J., & Kiess, W. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.07.008 · Cited by 471 · cited 1×
“Adiponectin, resistin, and visfatin are known to be directly involved in the metabolism of the adipose tissue, 15,16 whereas TNF-a , IL-6, hs-CRP, and MCP-1 are the pro-inflammatory and acute-phase reactants, 17 and oxidized LDL is an oxidative stress marker.”
Adiponectin: a key fat-derived molecule regulating inflammation
Tilg, H., & Wolf, A. M. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.245 · Cited by 71
Cited by
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“Resistin and FGF21 levels tend to be highest in the MUHO population (148, 208).”
BackgroundKalinkovich, A., & Livshits, G. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.008 · Cited by 882
Fu, J., Li, Y., Esangbedo, I. C., Li, G., Feng, D., Li, L., Xu, L., Han, L., Li, M., Li, C., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009169 · Cited by 37
“Given its important role in metabolism, adiponectin has gained a great deal of attention in recent clinical studies of the MHO phenotype.(24,39,41,49,51,52) We also found a significant association between higher adiponectin levels and the MHO phenotype in our large pediatric Chinese cohort, which has heretofore never…”
BackgroundResult
Metadata
- Authors
- Indulekha, K., Surendar, J., Anjana, R. M., Geetha, L., Gokulakrishnan, K., Pradeepa, R., & Mohan, V.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2015-02
- Volume
- 17
- Issue
- 2
- Pages
- 134-141
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1475317210
- Cited by
- 40
- References
- 9
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.